FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
77,99 -0,12 (-0,15%) Bitcoin EUR
59.236,57 +88,35 (+0,15%)
Kamada Ltd. (KMDA)
| Chiusura precedente | 5,56 |
| Aperto | 5,62 |
| Denaro | 5,68 x 100 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 5,52 - 5,77 |
| Intervallo di 52 settimane | 4,08 - 6,53 |
| Volume | |
| Media Volume | 21.083 |
| Capitalizzazione | 330,507M |
| Beta (5 anni mensile) | 0,24 |
| Rapporto PE (ttm) | 38,33 |
| EPS (ttm) | 0,15 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,00 |
GlobeNewswireKamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S.New Clinical Data Highlighting Five-year Real-world Survival Benefits of High Risk CMV Mismatch Lung Transplant Patients Receiving CYTOGAM were Presented at IDWeek 2023Company Establishes Scientific Advisory Board Focused on U.S. Clinical Programs for CYTOGAM REHOVOT, Israel and HOBOKEN, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ
- GlobeNewswire
Kamada Provides Corporate Update on its Israel Operations
REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of product
- GlobeNewswire
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a lea
